Fabrice André
- Cancer Research top 0.01%
- Cancer Genomics and Diagnostics 140
- Breast Cancer Treatment Studies 125
- Oncology top 0.01%
- HER2/EGFR in Cancer Research 142
- Cancer Treatment and Pharmacology 113
- Cancer Immunotherapy and Biomarkers 53
- Pulmonary and Respiratory Medicine top 0.02%
- Advanced Breast Cancer Therapies 187
- Lung Cancer Treatments and Mutations 78
- Immunology top 0.2%
- Genetics top 0.2%
-
- PI3K/AKT/mTOR signaling in cancer 47
- Co-authors
- Jean‐Charles SoriaLaurence ZitvogelLajos PusztaiMassimo CristofanilliNicholas C. TurnerSibylle LoiblSuzette DelalogeSherene Loi
- Journals
- Journal of Clinical Oncology (132 papers)Annals of Oncology (114 papers)Cancer Research (89 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Fabrice André
647 papers receiving 37.4k citations
Hit Papers
Peers
Comparison fields: 5 of 183
- Cancer Research 14.1k
- Oncology 20.5k
- Pulmonary and Respiratory Medicine 13.0k
- Immunology 4.8k
- Genetics 2.3k
Countries citing papers authored by Fabrice André
This map shows the geographic impact of Fabrice André's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabrice André with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabrice André more than expected).
Fields of papers citing papers by Fabrice André
This network shows the impact of papers produced by Fabrice André. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabrice André. The network helps show where Fabrice André may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fabrice André, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancerbreakdown → | 2019 | 1565 |
| 2 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trialbreakdown → | 2018 | 401 |
| 3 | 2017 | 115 | |
| 4 | 2016 | 111 | |
| 5 | 2016 | 11 | |
| 6 | 2013 | 251 | |
| 7 | 2013 | 148 | |
| 8 | 2013 | 33 | |
| 9 | 2013 | 247 | |
| 10 | 2013 | 75 | |
| 11 | 2011 | 54 | |
| 12 | 2011 | 44 | |
| 13 | 2011 | 93 | |
| 14 | 2010 | 23 | |
| 15 | 2010 | 87 | |
| 16 | 2010 | 148 | |
| 17 | 2009 | 248 | |
| 18 | 2007 | 100 | |
| 19 | 1988 | 45 | |
| 20 | Contribution à l'étude de la biologie et de la pêche du céteau Dicologoglossa cuneata (MOREAU) dans le sud du Golfe de Gascogne | 1974 | 0 |
About Fabrice André
Fabrice André is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 675 papers that have together received 38.0k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (187 papers), HER2/EGFR in Cancer Research (142 papers), Cancer Genomics and Diagnostics (140 papers), Breast Cancer Treatment Studies (125 papers), Cancer Treatment and Pharmacology (113 papers), Lung Cancer Treatments and Mutations (78 papers), Cancer Immunotherapy and Biomarkers (53 papers) and PI3K/AKT/mTOR signaling in cancer (47 papers). The work is most often cited by research in Cancer Research (14.1k citations), Oncology (20.5k citations), Pulmonary and Respiratory Medicine (13.0k citations), Immunology (4.8k citations) and Genetics (2.3k citations). Fabrice André has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Jean‐Charles Soria, Laurence Zitvogel, Lajos Pusztai, Massimo Cristofanilli, Nicholas C. Turner, Sibylle Loibl, Suzette Delaloge, Sherene Loi, Gabriel N. Hortobágyi and W. Fraser Symmans. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.